[DARA] DARA Biosciences, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 17.39 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.88 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart DARA

Refresh chart

Description: DARA BioSciences, Inc., a development stage biopharmaceutical company, develops and commercializes oncology treatment and supportive care pharmaceutical products in the United States. It offers Soltamox for the chronic treatment of breast cancer or for cancer prevention in certain susceptible breast cancer subgroups. The company?s oncology supportive care pharmaceutical products comprise Gelclair, an oral gel for the treatment of oral mucositis; and Bionect for the management of irritation of the skin, as well as first and second degree burns. Its clinical development programs include KRN5500, a novel, non-narcotic/non-opioid intravenous product for the treatment of cancer patients with painful chronic chemotherapy induced peripheral neuropathy, which has completed Phase 2a development; and DB959, a drug candidate for the treatment of type 2 diabetes and dyslipidemia. DARA BioSciences, Inc. was incorporated in 2002 and is headquartered in Raleigh, North Carolina.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding19.76 M EPS-0.52 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 59.41% Sales Growth - Q/Q-9.19% P/E-1.69
P/E To EPS Growth P/S7.32 P/BV1.56 Price/Cash Per Share
Price/Free Cash Flow-2.18 ROA-64.33% ROE-85.14% ROI
Current Ratio3.11 Quick Ratio3.05 Long Term Debt/Equity Debt Ratio0.32
Gross Margin77.32% Operating Margin-404.84% Net Profit Margin-399.41% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-20 K Cash From Investing Activities Cash From Operating Activities-2.15 M Gross Profit500 K
Net Profit-3.15 M Operating Profit-3.13 M Total Assets14.76 M Total Current Assets10.95 M
Total Current Liabilities3.52 M Total Debt30 K Total Liabilities3.61 M Total Revenue650 K
Technical Data
High 52 week0.99 Low 52 week0.68 Last close0.88 Last change-6.38%
RSI54.55 Average true range0.05 Beta0.4 Volume
Simple moving average 20 days-2.11% Simple moving average 50 days2.3% Simple moving average 200 days3.88%
Performance Data
Performance Week-4.35% Performance Month3.53% Performance Quart4.76% Performance Half-9.28%
Performance Year10% Performance Year-to-date0% Volatility daily2.26% Volatility weekly5.06%
Volatility monthly10.37% Volatility yearly35.91% Relative Volume0% Average Volume85.14 K
New High New Low

News

2015-12-10 05:23:21 | Merger Update: Acquisition of DARA BioSciences

2015-12-10 05:23:21 | Closing of acquisition

2015-12-10 05:23:21 | Merger Update: Amount of New Shares to be Issued

2015-12-10 05:23:21 | Supplemental Disclosure

2015-12-08 13:16:54 | DARA BIOSCIENCES, INC. Financials

2015-12-04 17:07:25 | MIDATECH PHARMA US INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting o

2015-12-03 11:14:40 | DARA BioSciences, Inc. Earnings Q3, 2015

2015-12-02 16:50:28 | DARA BioSciences Announces Stockholder Approval of Merger With Midatech

2015-12-02 16:32:38 | DARA BIOSCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events, Financi

2015-12-02 16:30:00 | DARA BioSciences Announces Stockholder Approval of Merger With Midatech

2015-11-18 16:31:59 | DARA BIOSCIENCES, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stan

2015-11-02 16:36:52 | DARA BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex

2015-11-02 16:30:00 | DARA BioSciences Announces Third Quarter 2015 Results

2015-10-06 08:00:00 | DARA BioSciences to Present at the 2015 Aegis Growth Conference on October 8, 2015

2015-10-05 08:00:00 | DARA BioSciences Announces U.S. Launch of OravigR miconazole, the First and Only Orally-Dissolving Buccal Tablet Available for Treatment of Adults With Oral Thrush

2015-09-23 16:30:00 | DARA BioSciences to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015

2015-09-02 16:30:00 | DARA BioSciences to Present at the 17th Annual Rodman and Renshaw Global Investment Conference on September 9, 2015

2015-08-12 16:15:00 | DARA BioSciences Announces Second Quarter 2015 Results

2015-08-10 08:00:00 | DARA BioSciences Announces Date and Time for Announcement of Second Quarter 2015 Results

2015-06-04 06:00:00 | DARA BioSciences Announces Proposed Acquisition Agreement With Midatech Pharma PLC, a UK Based Specialty Pharmaceutical Company

2015-05-13 16:15:00 | DARA BioSciences Announces First Quarter 2015 Results

2015-05-12 07:00:00 | DARA BioSciences Announces Date and Time for Announcement of First Quarter 2015 Results